Corcept Therapeutics
149 Commonwealth Drive
Menlo Park
California
94025
United States
Website: http://www.corcept.com/
Email: info@corcept.com
About Corcept Therapeutics
Corcept is leading the discovery and development of drugs that modulate the effects of cortisol.
Cortisol dysregulation plays an important role in a variety of endocrine, metabolic, oncologic, psychiatric, and ophthalmologic diseases. Corcept leads the field in the research and development of selective glucocorticoid receptor (GR) antagonists, having discovered more than 500 proprietary molecules since being founded in 1998.
Corcept is committed to improving patient lives through the discovery and development of drugs that address serious unmet medical needs related to excess cortisol activity. To support this mission, Corcept collaborates with numerous basic scientists and clinical researchers to find better ways to improve patient lives.
Through our collaborations with researchers around the world, more than 30 studies are underway to investigate the potential benefits GR antagonists may have in the treatment of serious and life-threatening diseases driven by cortisol dysregulation.
Stock Symbol: CORT
231 articles about Corcept Therapeutics
-
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
5/3/2023
Corcept Therapeutics Incorporated (NASDAQ: CORT) today reported its results for the quarter ended March 31, 2023.
-
Corcept Therapeutics to Announce First Quarter 2023 Financial Results, Provide Corporate Update and Host Conference Call
4/26/2023
Corcept Therapeutics Incorporated announced it will report first quarter financial results and provide a corporate update on May 3, 2023.
-
Corcept Therapeutics Announces Final Results of Tender Offer
4/5/2023
Corcept Therapeutics Incorporated announced the final results of its previously announced tender offer to purchase up to 7,500,000 shares of its common stock, par value $0.001 per share, at a price not greater than $22.00 nor less than $19.25 per share, in cash, less any applicable withholding taxes and without interest, which expired one minute after 11:59 p.m., New York City time, on March 31, 2023.
-
Corcept Therapeutics Announces Preliminary Results of Tender Offer
4/3/2023
Corcept Therapeutics announced the preliminary results of its previously announced tender offer to purchase up to 7,500,000 shares of its common stock, par value $0.001 per share, at a price not greater than $22.00 nor less than $19.25 per share, in cash, less any applicable withholding taxes and without interest, which expired one minute after 11:59 p.m., New York City time, on March 31, 2023.
-
Corcept Therapeutics Initiates CATALYST Clinical Trial
3/28/2023
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that it has initiated CATALYST, a 1,000-patient, Phase 4 trial examining the prevalence of hypercortisolism in patients with difficult to control type 2 diabetes.
-
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate Update
2/28/2023
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2022.
-
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call
2/14/2023
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2022 financial results and provide a corporate update on February 28, 2023.
-
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
12/8/2022
Corcept Therapeutics Incorporated today announced that it has entered into an agreement with Hikma Pharmaceuticals USA Inc. ("Hikma") resolving patent litigation related to Korlym ®, Corcept’s medication for the treatment of patients with Cushing’s syndrome.
-
Corcept Therapeutics Provides Miricorilant Clinical Development Update
12/8/2022
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced an update to its programs evaluating the proprietary selective cortisol modulator miricorilant in patients with antipsychotic-induced weight gain (AIWG) and non-alcoholic steatohepatitis (NASH).
-
Corcept Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
11/3/2022
Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, reported its results for the quarter ended September 30, 2022.
-
Corcept Therapeutics to Announce Third Quarter 2022 Financial Results, Provide Corporate Update and Host Conference Call
10/27/2022
Corcept Therapeutics Incorporated announced it will report third quarter financial results and provide a corporate update on November 3, 2022.
-
Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)
10/11/2022
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that it has initiated DAZALS – a Phase 2 trial of its proprietary selective cortisol modulator dazucorilant in patients with amyotrophic lateral sclerosis (ALS).
-
Corcept Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
8/3/2022
Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, reported its results for the quarter ended June 30, 2022.
-
Corcept Therapeutics to Announce Second Quarter 2022 Financial Results, Provide Corporate Update and Host Conference Call
7/27/2022
Corcept Therapeutics Incorporated announced it will report second quarter financial results and provide a corporate update on August 3, 2022.
-
Otsuka and Lunbeck report positive Phase III results in agitation in Alzheimer's, Acer's vEDS program hits Phase III and BridgeBio's primary hyperoxaluria type 1 program progresses.
-
Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer
6/29/2022
Corcept Therapeutics Incorporated announced that it has initiated ROSELLA, a pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.
-
Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
6/6/2022
Corcept Therapeutics Incorporated announced that, following consultation with the U.S. Food and Drug Administration, it will start a registrational Phase 3 trial of relacorilant plus nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.
-
Corcept Therapeutics Announces First Quarter 2022 Financial Results And Provides Corporate Update
5/5/2022
Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol, reported its results for the quarter ended March 31, 2022.
-
Corcept Therapeutics Announces Appointment of Three Senior Leaders
4/7/2022
Corcept Therapeutics Incorporated announced the appointment of three individuals to Commercial and Development leadership roles.
-
Corcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant in Patients with Antipsychotic-Induced Weight Gain
4/4/2022
Corcept Therapeutics Incorporated today announced completion of enrollment in GRATITUDE – the company’s double-blind, placebo-controlled trial of its proprietary, selective cortisol modulator miricorilant as a potential treatment for patients with weight gain caused by antipsychotic medication use.